Related Experiment Video
Updated: Aug 14, 2026

Analyzing and Building Nucleic Acid Structures with 3DNA
Published on: April 26, 2013
Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Abstract:
Transcription factors of the NFAT family regulate the production of effector proteins that coordinate the immune response. The immunosuppressive drugs FK506 and cyclosporin A (CsA) act by blocking a Ca2+-mediated signalling pathway leading to NFAT. Although FK506 and CsA have enabled human organs to be transplanted routinely, the toxic side-effects of these drugs limit their usage. This toxicity might be absent in antagonists that target NFAT directly. As a first step in the structure-based search for NFAT antagonists, we now report the identification and solution structure of a 20K domain of NFATc (NFATc-DBD) that is both necessary and sufficient to bind DNA and activate transcription cooperatively. Although the overall fold of the NFATc DNA-binding domain is related to that of NF-kappaB p50 (refs 2, 3), the two proteins use significantly different strategies for DNA recognition. On the basis of these results, we present a model for the cooperative complex formed between NFAT and the mitogenic transcription factor AP-1 on the interleukin-2 enhancer.
Insights
Researchers identified the NFATc DNA-binding domain (NFATc-DBD), crucial for immune response regulation. This discovery aids in developing new drugs targeting NFAT directly, potentially reducing immunosuppressive therapy side effects.
Area of Science:
- Molecular Biology
- Immunology
- Structural Biology
Background:
- Nuclear factor of activated T-cells (NFAT) proteins regulate immune responses.
- Current immunosuppressants like FK506 and cyclosporin A (CsA) target NFAT signaling but cause toxic side effects.
- Direct NFAT antagonists could offer safer alternatives.
Purpose of the Study:
- To identify and characterize the DNA-binding domain of NFATc (NFATc-DBD).
- To determine the solution structure of NFATc-DBD for structure-based drug design.
- To understand NFAT's DNA binding and transcriptional activation mechanisms.
Main Methods:
- Protein expression and purification of NFATc-DBD.
- Nuclear Magnetic Resonance (NMR) spectroscopy for structure determination.
- Comparative structural analysis with NF-kappaB p50.
Main Results:
- The 20 kDa NFATc-DNA binding domain (NFATc-DBD) was identified as necessary and sufficient for DNA binding and transcriptional activation.
- The solution structure of NFATc-DBD was determined.
- NFATc-DBD employs a distinct DNA recognition strategy compared to NF-kappaB p50.
- A model for the cooperative complex of NFAT and AP-1 on the interleukin-2 enhancer was proposed.
Conclusions:
- The NFATc-DBD structure provides a basis for designing novel NFAT-targeted immunosuppressants.
- Understanding NFAT's DNA binding mechanism is key to developing safer therapeutic strategies.
- This work facilitates the development of antagonists with potentially reduced toxicity compared to current drugs.
More Related Videos
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
06:38High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy
Published on: February 7, 2019
Related Concept Videos
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Cis-regulatory Sequences
Cooperative Binding of Transcription Regulators
Co-activators and Co-repressors
Cooperative Binding of Transcription Regulators
Nucleoid